100278-51-1

Basic information

• Product Name: ethyl 4-[(4-methoxybenzoyl)amino]benzoate
• Synonyms: ethyl 4-[(4-methoxybenzoyl)amino]benzoate
• CAS NO: 100278-51-1
• Molecular Formula: C₁₇H₁₇NO₄
• Molecular Weight: 299.32118
• Mol File: 100278-51-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 388.5°C at 760 mmHg
• Flash Point: 188.8°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 3.04E-06mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: ethyl 4-[(4-methoxybenzoyl)amino]benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-[(4-methoxybenzoyl)amino]benzoate(100278-51-1)
• EPA Substance Registry System: ethyl 4-[(4-methoxybenzoyl)amino]benzoate(100278-51-1)

Safety Data

• Hazardous Substances Data: 100278-51-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H17NO4/c1-3-22-17(20)13-4-8-14(9-5-13)18-16(19)12-6-10-15(21-2)11-7-12/h4-11H,3H2,1-2H3,(H,18,19)

Upstream product

• 100-09-4 4-methoxybenzoic acid 
• 94-09-7 p-aminoethylbenzoate 
• 100-07-2 4-methoxy-benzoyl chloride 

Downstream Products

• 100278-53-3 4-(4-methoxybenzoylamino)benzoyl hydrazine 
• 109633-06-9 C₂₂H₂₀N₄O₃S 
• 187274-36-8 C₁₉H₂₀N₄O₃S 
• 466690-15-3 C₂₃H₂₂N₄O₃S 
• 466690-16-4 C₂₃H₂₂N₄O₄S 

Relevant articles and documents

Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel ind

Pursuing on our efforts regarding development of novel multikinase inhibitors, herein we report the design and synthesis of novel 2-indolinone-based ureides 6a-u and amides 10a-j. In this work we adopt a hybridization strategy between type IIA PTK inhibit

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

On the basis of the comparison of the structure of the Bim BH3: Bcl-x L complex and that of the ABT-737: Bcl-xL complex, a series of class A compounds were designed. These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3. These residues had shown themselves to be relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays. Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. Then class B compounds were synthesized by modifying the structure of the most effective class A compound, A-4. Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds had. They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-x L, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins. Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells. Finally, our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.

Synthesis and antimicrobial activity of some 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted 1,3,4-thiadiazole derivatives

Various new 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted-1,3,4-thiadiazole derivatives were synthesized and evaluated for their in vitro antimicrobial activity. The structure of compounds was confirmed by elemental analyses and spectroscopic